Conference Call and Webcast on Wednesday, March 5, 2014 at 4:30 p.m.
Eastern Time
PLYMOUTH, Mich.--(BUSINESS WIRE)--
Esperion Therapeutics, Inc. (NASDAQ:ESPR), a clinical-stage
biopharmaceutical company focused on developing and commercializing
first-in-class, oral, low-density lipoprotein cholesterol (LDL-C)
lowering therapies for the treatment of hypercholesterolemia, today
announced that it will host a conference call and webcast to provide
program development updates and discuss financial results for the fourth
quarter and full year ended Dec. 31, 2013. The webcast will take place
following NASDAQ Market close on Wednesday, March 5, 2014 at 4:30 p.m.
Eastern Time.
The call can be accessed by dialing (877) 312-7508 (domestic) or (253)
237-1184 (international) five minutes prior to the start of the call and
providing access code 56291756. A live, listen-only webcast of the
conference call can be accessed on the investor relations section of the
Esperion website at www.esperion.com/events.
A webcast replay of the call will be available approximately two hours
after completion of the call and will be archived on the company's
website for two weeks.
About Esperion Therapeutics
Esperion Therapeutics, Inc. is a clinical stage biopharmaceutical
company focused on developing and commercializing first-in-class, oral,
low-density lipoprotein cholesterol (LDL-C) lowering therapies for the
treatment of patients with hypercholesterolemia and other
cardiometabolic risk markers. ETC-1002, Esperion's lead product
candidate, is a unique, first-in-class, orally available, once-daily
small molecule designed to lower LDL-C levels and avoid the side effects
associated with LDL-C lowering therapies currently available. ETC-1002
is being developed primarily for patients intolerant of statins with
elevated levels of LDL-C. Phase 2b clinical trials for ETC-1002 are
currently underway and build upon a successful and comprehensive Phase 1
and Phase 2 program. For more information, please visit www.esperion.com.
Forward Looking Statements
This press release contains forward-looking statements that are made
pursuant to the safe harbor provisions of the federal securities laws,
including statements regarding the therapeutic potential of ETC-1002.
Any statements contained in this press release that are not statements
of historical fact may be deemed to be forward-looking statements.
Forward-looking statements involve risks and uncertainties that could
cause Esperion's actual results to differ significantly from those
projected, including, without limitation, the risk that unanticipated
developments could interfere with the development (and
commercialization) of ETC-1002, as well as other risks detailed in
Esperion's filings with the Securities and Exchange Commission,
including our Quarterly Report on Form 10-Q filed with the Securities
and Exchange Commission on November 6, 2013. You are cautioned not to
place undue reliance on the forward-looking statements, which speak only
as of the date of this release. Esperion disclaims any obligation or
undertaking to update or revise any forward-looking statements contained
in this press release, other than to the extent required by law.
W2O Group
Elliot Fox, 212-257-6724
efox@w2ogroup.com
Source: Esperion Therapeutics, Inc.
News Provided by Acquire Media